Cetera Trust Company, N.A Neurocrine Biosciences Inc Call Options Transaction History
Cetera Trust Company, N.A
- $166 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NBIX
# of Institutions
635Shares Held
94.8MCall Options Held
472KPut Options Held
245K-
Black Rock Inc. New York, NY13.8MShares$2.02 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.93MShares$1.46 Billion0.03% of portfolio
-
State Street Corp Boston, MA3.99MShares$586 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.3MShares$337 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.25MShares$331 Million0.49% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $14B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...